Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph II E7080 W/ 131I-Refractory Thyroid Ca Whether an Oral 18 mg Comparable to a 24-mg Dose.

Protocol: OSU-15245

Full Title

A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile

Thyroid Cancer Endocrine Cancers